高血流和透析液流速持续静脉-静脉血液透析时头孢吡肟浓度较低。
Low cefepime concentrations during high blood and dialysate flow continuous venovenous hemodialysis.
机构信息
University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA.
出版信息
Antimicrob Agents Chemother. 2012 Apr;56(4):2178-80. doi: 10.1128/AAC.05987-11. Epub 2012 Jan 30.
Abstract
Dosing of cefepime during high blood flow (Qb; 300 ml/min), high dialysate flow (Qd; 3 liter/h) continuous venovenous hemodialysis (CVVHD) is undefined. Six patients on CVVHD had serum and effluent cefepime concentrations measured at 0.5, 1, 2, 6, and 12 h after dosing. Three patients had cefepime concentrations less than the MIC for Pseudomonas aeruginosa. A dose of 2,000 mg every 12 h or 1,000 mg every 8 h may increase time at a therapeutic concentration.
摘要
在高血流（Qb；300ml/min）、高透析液流量（Qd；3L/h）行连续性静脉-静脉血液透析（CVVHD）时，头孢吡肟的剂量尚未明确。6 名接受 CVVHD 的患者在给药后 0.5、1、2、6 和 12 小时测量血清和流出液中的头孢吡肟浓度。3 名患者的头孢吡肟浓度低于铜绿假单胞菌的 MIC。每 12 小时给予 2000mg 或每 8 小时给予 1000mg 剂量可能会增加达到治疗浓度的时间。
相似文献
1
Low cefepime concentrations during high blood and dialysate flow continuous venovenous hemodialysis.高血流和透析液流速持续静脉-静脉血液透析时头孢吡肟浓度较低。
Antimicrob Agents Chemother. 2012 Apr;56(4):2178-80. doi: 10.1128/AAC.05987-11. Epub 2012 Jan 30.
2
Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.头孢吡肟在持续静静脉血液透析滤过过程中的药代动力学
Antimicrob Agents Chemother. 1997 Nov;41(11):2424-7. doi: 10.1128/AAC.41.11.2424.
3
Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.危重患者持续肾脏替代治疗期间头孢吡肟的药代动力学
Antimicrob Agents Chemother. 2001 Nov;45(11):3148-55. doi: 10.1128/AAC.45.11.3148-3155.2001.
4
Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.连续肾脏替代治疗的危重症患者中头孢吡肟延长输注的药代动力学和药效学：一项前瞻性、开放标签研究。
Pharmacotherapy. 2019 Nov;39(11):1066-1076. doi: 10.1002/phar.2332. Epub 2019 Oct 22.
5
Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.头孢吡肟与连续性肾脏替代治疗（CRRT）：两种CRRT膜的体外通透性及4例危重症患者的药代动力学
Clin Ther. 2005 May;27(5):599-608. doi: 10.1016/j.clinthera.2005.05.004.
6
Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing.重症脓毒症患者血浆头孢吡肟水平较低：药代动力学模型表明，调整给药方案可提高谷浓度。
Antimicrob Agents Chemother. 1999 Oct;43(10):2559-61. doi: 10.1128/AAC.43.10.2559.
7
Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.重症监护病房中头孢吡肟给药方案的药代动力学-药效学原理
J Antimicrob Chemother. 2006 Nov;58(5):987-93. doi: 10.1093/jac/dkl349. Epub 2006 Aug 30.
8
Prospective monitoring of cefepime in intensive care unit adult patients.重症监护病房成年患者头孢吡肟的前瞻性监测。
Crit Care. 2010;14(2):R51. doi: 10.1186/cc8941. Epub 2010 Apr 1.
9
Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.头孢吡肟治疗铜绿假单胞菌感染患者的临床药效动力学。
Antimicrob Agents Chemother. 2010 Mar;54(3):1111-6. doi: 10.1128/AAC.01183-09. Epub 2009 Dec 28.
10
Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model.在药效学感染模型中，针对铜绿假单胞菌临床分离株，评估头孢吡肟的几种给药方案，并对肾功能进行各种模拟。
Antimicrob Agents Chemother. 1999 Jan;43(1):129-33. doi: 10.1128/AAC.43.1.129.
引用本文的文献
1
assessment and simulation to guide cefepime-taniborbactam dosing recommendations for patients receiving continuous renal replacement therapy.评估与模拟，以指导接受连续性肾脏替代治疗的患者使用头孢吡肟-他尼硼巴坦的给药建议。
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0006125. doi: 10.1128/aac.00061-25. Epub 2025 May 5.
2
assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations.连续肾脏替代治疗期间舒巴坦-杜洛巴坦清除率的评估，以指导给药建议。
Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0167423. doi: 10.1128/aac.01674-23. Epub 2024 Dec 10.
3
Treatment of Acute Kidney Injury: A Review of Current Approaches and Emerging Innovations.急性肾损伤的治疗：当前方法与新兴创新综述
J Clin Med. 2024 Apr 23;13(9):2455. doi: 10.3390/jcm13092455.
4
Cefepime Extraction by Extracorporeal Life Support Circuits.体外生命支持回路对头孢吡肟的萃取。
J Extra Corpor Technol. 2022 Sep;54(3):212-222. doi: 10.1182/ject-212-222.
5
Cefepime Pharmacokinetics in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy.头孢吡肟在接受连续肾脏替代治疗的危重症儿科患者中的药代动力学。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02006-18. Print 2019 Apr.
6
Clinical implications of antibiotic pharmacokinetic principles in the critically ill.抗生素药代动力学原理在危重病患者中的临床意义。
Intensive Care Med. 2013 Dec;39(12):2070-82. doi: 10.1007/s00134-013-3088-4. Epub 2013 Sep 18.
本文引用的文献
1
Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.推荐的β-内酰胺方案在接受连续肾脏替代治疗的脓毒症患者中是不足够的。
Crit Care. 2011;15(3):R137. doi: 10.1186/cc10257. Epub 2011 Jun 6.
2
Intensity of renal support in critically ill patients with acute kidney injury.急性肾损伤危重症患者的肾脏支持强度
N Engl J Med. 2008 Jul 3;359(1):7-20. doi: 10.1056/NEJMoa0802639. Epub 2008 May 20.
3
Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.评估抑制曲线下面积（AUIC）和高于最低抑菌浓度的时间（T>MIC）作为头孢吡肟和头孢他啶治疗严重细菌感染疗效预测指标的研究
Int J Antimicrob Agents. 2008 Apr;31(4):345-51. doi: 10.1016/j.ijantimicag.2007.12.009. Epub 2008 Mar 4.
4
Intermittent versus continuous renal replacement therapy for acute renal failure in adults.间歇性与连续性肾脏替代疗法治疗成人急性肾衰竭
Cochrane Database Syst Rev. 2007 Jul 18(3):CD003773. doi: 10.1002/14651858.CD003773.pub3.
5
Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.接受持续肾脏替代治疗的重症成年患者的抗生素给药
Clin Infect Dis. 2005 Oct 15;41(8):1159-66. doi: 10.1086/444500. Epub 2005 Sep 12.
6
The NxStage System One.NxStage 系统一号机
Semin Dial. 2004 Mar-Apr;17(2):167-70. doi: 10.1111/j.0894-0959.2004.17220.x.
7
Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.危重患者持续肾脏替代治疗期间头孢吡肟的药代动力学
Antimicrob Agents Chemother. 2001 Nov;45(11):3148-55. doi: 10.1128/AAC.45.11.3148-3155.2001.
8
Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.头孢吡肟在持续静静脉血液透析滤过过程中的药代动力学
Antimicrob Agents Chemother. 1997 Nov;41(11):2424-7. doi: 10.1128/AAC.41.11.2424.
Zotero 插件